Arexvy疫苗于2023年获得美国FDA批准,用于预防60岁及以上人群的RSV相关下呼吸道疾病。 这项研究为制定RSV疫苗的接种策略提供了重要依据,表明单剂接种可能在多个季节中提供持续保护,减少老年人群的疾病负担。
2024年Q1疫苗业务呼吸道RSV疫苗Arexvy增长22%,带状疱疹Shingrix创销售额纪录!疫苗业务已成为葛兰素史克业绩增长的核心驱动力,带疱疫苗销售额9.45亿英镑,合11.8亿美元,同比增长18%;RSV疫苗销售额1.82亿英镑,合2.28亿美元。 带状疱疹疫苗在美国以外的3...
今日公布的结果显示,接种GSK单剂RSV疫苗在三个RSV完整流行季中的累积保护效力具有临床意义。与安慰剂相比,该疫苗对于RSV引发的下呼吸道疾病(RSV-LRTD)的保护效力达到62.9%(97.5%CI:46.7-74.8,48/12,468vs215/12,498),对于重度RSV-LRTD患者的保护效力为67.4%(95%CI:42.4-82.7,15/12,468vs75/12,498)。在第...
GSK releases strong efficacy data for older adult vaccine candidate RSV OA ahead of IDWeek2022 conference presentation.
‘We’re aiming to protect even more children’: Research starts on second-generation malaria vaccine to prevent most severe form of disease ‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’ ‘It’s insidious and it’s getting worse’: AMR and the ...
GSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50 to 5...
GSK shares positive data for AREXVY, its respiratory syncytial virus older adult vaccine, indicating protection over two RSV seasons
GSK is looking to ride the momentum from its RSV vaccine sales into 2024 and beyond. Meanwhile, it has cut three infectious disease candidates from its pipeline, two of which ...
GSK held an investor and analyst call hosted by Hal Barron, Chief Scientific Officer and President R&D, Roger Connor, President, GSK Vaccines, and Emmanuel Hanon, SVP and Head of Vaccines R&D, and discussed data on two respiratory syncytial virus (RSV) vaccine candidates to be presented at ID...
After years of vaccine drought for respiratory syncytial virus (RSV), we are now on the brink of a deluge. GSK's vaccine candidate that protects older adults from RSV-related diseases received approval from the US Food and Drug Administration on May 3. The firm says it expects that the ...